Skip to contentA
Anika Therapeutics, Inc.
A
ANIKAnika Therapeutics, Inc. Q4 2011 · 10-K
Revenue$18.44M$18.44Mno prior Q4 2010 on file−0.1% vs Q3 2011 Net Income$2.88M$2.88M
No earnings release is on file for this quarter. Its figures came with the 10-K.
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Anika Therapeutics, Inc. · CIK 898437 · Engraved from SEC EDGAR
−3.1% vs Q3 2011
EPS Diluted$0.21$0.21no prior Q4 2010 on file−4.5% vs Q3 2011 Operating Incomederived$4,915,784— Operating Cash Flowderived$7,307,321+93.9% Free Cash Flowderived$6,860,925+144.9% Margins · derivedGross margin57.5%
Operating margin26.7%
Net margin15.6%
ended Dec 31, 2011 · filed Mar 13, 2012 · 73 d after period end